GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (CHIX:PCIBo) » Definitions » Enterprise Value

PCI Biotech Holding ASA (CHIX:PCIBO) Enterprise Value : kr15.51 Mil (As of May. 22, 2024)


View and export this data going back to 2017. Start your Free Trial

What is PCI Biotech Holding ASA Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PCI Biotech Holding ASA's Enterprise Value is kr15.51 Mil. PCI Biotech Holding ASA's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was kr-30.35 Mil. Therefore, PCI Biotech Holding ASA's EV-to-EBIT ratio for today is -0.51.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, PCI Biotech Holding ASA's Enterprise Value is kr15.51 Mil. PCI Biotech Holding ASA's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was kr-29.85 Mil. Therefore, PCI Biotech Holding ASA's EV-to-EBITDA ratio for today is -0.52.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, PCI Biotech Holding ASA's Enterprise Value is kr15.51 Mil. PCI Biotech Holding ASA's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was kr0.00 Mil. Therefore, PCI Biotech Holding ASA's EV-to-Revenue ratio for today is .


PCI Biotech Holding ASA Enterprise Value Historical Data

The historical data trend for PCI Biotech Holding ASA's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Enterprise Value Chart

PCI Biotech Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,565.98 856.78 844.15 16.47 31.19

PCI Biotech Holding ASA Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.88 16.47 21.22 26.66 31.19

Competitive Comparison of PCI Biotech Holding ASA's Enterprise Value

For the Biotechnology subindustry, PCI Biotech Holding ASA's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Enterprise Value distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Enterprise Value falls into.



PCI Biotech Holding ASA Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

PCI Biotech Holding ASA's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

PCI Biotech Holding ASA's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PCI Biotech Holding ASA  (CHIX:PCIBo) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

PCI Biotech Holding ASA's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=15.511/-30.349
=-0.51

PCI Biotech Holding ASA's current Enterprise Value is kr15.51 Mil.
PCI Biotech Holding ASA's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-30.35 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

PCI Biotech Holding ASA's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=15.511/-29.847
=-0.52

PCI Biotech Holding ASA's current Enterprise Value is kr15.51 Mil.
PCI Biotech Holding ASA's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-29.85 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

PCI Biotech Holding ASA's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=15.511/0
=

PCI Biotech Holding ASA's current Enterprise Value is kr15.51 Mil.
PCI Biotech Holding ASA's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PCI Biotech Holding ASA Enterprise Value Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA (CHIX:PCIBO) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (CHIX:PCIBO) Headlines

No Headlines